Organization
Sumitomo Pharma
9 clinical trials
Clinical trial
Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia PatientsStatus: Terminated, Estimated PCD: 2022-11-22
Clinical trial
A Randomized, Double-blind, Parallel-group, Placebo Controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in Acutely Psychotic Patients With Schizophrenia, Followed by an Open-label Extension PhaseStatus: Terminated, Estimated PCD: 2023-10-12
Clinical trial
A 52-week, Open-label Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in JapanStatus: Terminated, Estimated PCD: 2024-03-21
Clinical trial
The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine: An Open-label, Single-arm And Multi-center Study for 16 WeeksStatus: Terminated, Estimated PCD: 2022-11-18
Clinical trial
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia: A Multi-Center, Prospective, Open-Label Study for 6 WeeksStatus: Completed, Estimated PCD: 2023-04-16
Clinical trial
The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia PatientsStatus: Completed, Estimated PCD: 2023-03-18
Clinical trial
A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's DiseaseStatus: Completed, Estimated PCD: 2022-11-30
Clinical trial
A Randomized, 6-Week, Multicenter, Double-Blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I DepressionStatus: Terminated, Estimated PCD: 2022-12-23
Clinical trial
A Single Center, Randomized, Double-blind, Placebo-controlled, First-in-human Phase 1 Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine "fH1/DSP-0546LP" After Intramuscular (IM) Administrations in Healthy AdultsStatus: Not yet recruiting, Estimated PCD: 2026-03-27